



**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN**

Company Announcement no. 17/2008

To: OMX Nordic Exchange Copenhagen

Hørsholm, Denmark, April 17, 2008

### **LifeCycle Pharma A/S announced successful completion of rights issue**

Hørsholm, Denmark, April 17, 2008; LifeCycle Pharma A/S (OMX: LCP) today announced the successful completion of its rights issue. The rights issue has been 99.62 % subscribed with 23,987,771 offered new shares of DKK 1 nominal value subscribed at DKK 17 per share. The gross proceeds to LCP from the right issue will be DKK 407.8 million, and the net proceeds will be approximately DKK 375.4 million.

The new shares will carry rights and be eligible for dividends as from the date the capital increase is registered with the Danish Commerce and Companies Agency, which has taken place today.

Following registration of 23,987,771 new shares of nominal value DKK 1 each, the nominal value of LCP's share capital totals DKK 56,092,945 corresponding to 56,092,945 shares of nominal value DKK 1 each.

It is expected that the new shares will be listed on the OMX Nordic Exchange Copenhagen on Monday, April 21, 2008, under the securities code of the existing shares, DK0060048148.

Joint Global Coordinators and Lead Managers, Danske Markets (division of Danske Bank A/S) and UBS Limited, have notified the company that no stabilization has taken place in relation to the preemptive rights issued by LCP.

### **About LifeCycle Pharma A/S ("LCP")**

LIFECYCLE PHARMA A/S  
KOGLE ALLÉ 4  
DK-2970 HØRSHOLM  
WWW.LIFECYCLEPHARMA.COM

TEL. +45 7033 3300  
FAX +45 3613 0319  
CVR. 26 52 77 67  
INFO@LCPHARMA.COM

page 1 of 3



LCP is an emerging specialty pharmaceutical company that, through innovative technologies, is able to rapidly develop a portfolio of differentiated products to meet the unique needs of key therapeutic markets and patient populations.

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN**

This includes products for immunosuppression, specifically organ transplantation, and to combat certain cardiovascular diseases. By using its unique and patented delivery technology, MeltDose<sup>®</sup>, LCP is able to develop drugs with enhanced absorption and thereby increased bioavailability. LCP has a cholesterol lowering product, Fenoglide<sup>™</sup>, currently on the U.S. market and a diversified near- and medium-term pipeline, including five product candidates in clinical trials and three in preclinical stages of development. LCP is listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX: LCP). For further information, please visit [www.lcpharma.com](http://www.lcpharma.com).

**For further information please contact:**

LifeCycle Pharma A/S  
Hans Christian Teisen  
EVP & CFO  
+45 20 30 69 85;  
E-mail: [hct@lcpharma.com](mailto:hct@lcpharma.com)

**Disclaimer**

This announcement is not a solicitation or an invitation to invest in LifeCycle Pharma A/S. Any subscription for shares shall be based on the offering circular prepared by the Company in connection with the Offering. These materials are not an offer for sale of securities. The securities have not been registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act. Any public offering of securities will be made by means of a prospectus that may be obtained from the issuer or selling security holder and that will contain detailed information about the company and management, as well as financial statements.

LIFECYCLE PHARMA A/S  
KOGLE ALLÉ 4  
DK-2970 HØRSBOLM  
WWW.LIFECYCLEPHARMA.COM

TEL. +45 7033 3300  
FAX +45 3613 0319  
CVR. 26 52 77 67  
INFO@LCPHARMA.COM

page 2 of 3



In any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any member State, the “Prospectus Directive”), this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive.

This communication is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ((i) and (ii) above together being referred to as “relevant persons”). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

LIFECYCLE PHARMA A/S  
KOGLE ALLÉ 4  
DK-2970 HØRSHOLM  
WWW.LIFECYCLEPHARMA.COM

TEL. +45 7033 3300  
FAX +45 3613 0319  
CVR. 26 52 77 67  
INFO@LCPHARMA.COM

page 3 of 3